Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116, 561–570 (2006).
  Medline CASGoogle Scholar
• 2 Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J. Endocrinol. 204, 105–114 (2010).•• Summarizes the involvement of GPER in diverse pathophysiological conditions.
  Medline CASGoogle Scholar
• 3 Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor throughout release of HB-EGF. Mol. Endocrinol. 14, 1649–1660 (2000).
  Medline CASGoogle Scholar
• 4 Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol. 308, 32–38 (2009).
  Medline CASGoogle Scholar
• 5 Bologa CG, Revankar CM, Young SM et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2, 207–212 (2006).
  Medline CASGoogle Scholar
• 6 Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J. Steroid Biochem. Mol. Biol. 109, 350–353 (2008).
  Medline CASGoogle Scholar
• 7 Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 7, 715–726 (2011).• Clarifies the role of GPER in different pathological conditions.
  Medline CASGoogle Scholar
• 8 Hammond R, Mauk R, Ninaci D, Nelson D, Gibbs RB. Chronic treatment with estrogen receptor agonists restores acquisition of a spatial learning task in young ovariectomized rats. Horm. Behav. 56, 309–314 (2009).
  Medline CASGoogle Scholar
• 9 Blasko E, Haskell CA, Leung S et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J. Neuroimmunol. 214, 67–77 (2009).
  Medline CASGoogle Scholar
• 10 Arterburn JB, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA. Discovery of selective probes and antagonists for G protein-coupled receptors for FPR/FPRL1 and GPR30. Curr. Top. Med. Chem. 9, 1227–1236 (2009).
  Medline CASGoogle Scholar
• 11 Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2. Lewis rats. Endocrinology 150, 3753–3758 (2009).
  Medline CASGoogle Scholar
• 12 Lappano R, Rosano C, Santolla MF et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr. Cancer Drug Targ. 12, 531–542 (2012).• Outlines the key role of GPER in cancer emergence and progression.
  Medline CASGoogle Scholar
• 13 Santolla MF, De Francesco EM, Lappano R, Rosano C, Abonante S, Maggiolini, M. Niacin activates the G protein-coupled estrogen receptor (GPER)-mediated signaling. Cell. Signal. 26(7), 1466–1475 (2014).
  Medline CASGoogle Scholar
• 14 Dennis MK, Field AS, Burai R et al. Identification of GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J. Steroid Biochem. Mol. Biol. 127, 358–366 (2011).• Defines structural diverse features between GPER agonists and antagonists.
  Medline CASGoogle Scholar
• 15 Huryn DM, Resnick LO, Wipf P. Contributions of academic laboratories to the discovery and development of chemical biology tools. J. Med. Chem. 56, 7161–7176 (2013).
  Medline CASGoogle Scholar
• 16 Burai R, Ramesh C, Nayak TK et al. Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30. PLoS ONE 7, e46861 (2012).• Adds more insights to define chemical features for the design of new GPER antagonists.
  Medline CASGoogle Scholar
• 17 Lappano R, Santolla MF, Pupo M et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Breast Cancer Res. 14, R12 (2012).• Describes the effects of GPER activation/inhibition in breast cancer.
  Medline CASGoogle Scholar
• 18 Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091–1103 (2008).
  Medline CASGoogle Scholar
• 19 Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).
  Medline CASGoogle Scholar
• 20 Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolin M. Recent advances in the rationale design of GPER ligands. Curr. Med. Chem. 19, 6199–6206 (2012).•• Describes the importance of rational design of selective GPER ligands, in order to dissect the functions mediated by this receptor.
  Medline CASGoogle Scholar
• 21 Murshudov GN, Skubák P, Lebedev AA et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355–367 (2011).
  Medline CASGoogle Scholar
• 22 Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell Endocrinol. 204, 105–114 (2010).
  Google Scholar
• 23 Chimento A, Casaburi I, Bartucci M et al. Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells. Cell Death Dis. 4, e747 (2013).
  Medline CASGoogle Scholar
• 24 Amaro AA, Esposito AI, Mirisola V et al. Endocrine disruptor agent nonyl phenol exerts an estrogen-like transcriptional activity on estrogen receptor positive breast cancer cells. Curr. Med. Chem. 21, 630–640 (2014).
  Medline CASGoogle Scholar
• 25 Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
  Medline CASGoogle Scholar
• 26 Lappano R, Recchia AG, De Francesco EM et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 6, e16631 (2011).
  Medline CASGoogle Scholar
• 27 Jirkovsky I, Humber LG, Baudy R. 4-Substituted-4H-pyrrolo[2,1-c][1,4]benzoxazines. J. Heterocyclic Chem. 13, 311–316 (1976).
  CASGoogle Scholar
• 28 Lancelot J-C, Rault S, Laduree D, Robba M. Pyrido[3,2-e]pyrrolo[1,2-a]pyrazines. Chem. Pharm. Bull. 33, 2798–2802 (1985).
  CASGoogle Scholar
• 29 Ren P-D, Pan S-F, Dong T-W, Wu S-H. The novel reduction systems: NaBH₄-SbCl₃ or NaBH₄-BiCl₃ for conversion of nitroarenes to primary amines. Synthetic Commun. 25, 3799–3803 (1995).
  CASGoogle Scholar
• 30 Dennis MK, Burai R, Ramesh C et al. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 5, 421–427 (2009).•• Identifies a GPER antagonist counteracting biological responses induced by estrogens.
  Medline CASGoogle Scholar
• 31 Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 15, 97–101 (2005).
  Medline CASGoogle Scholar
• 32 Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
  Medline CASGoogle Scholar
• 33 Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr. J. 56, 1–7 (2009).
  MedlineGoogle Scholar